Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

"Declaration of interest: Wojciech Jurczak: Research Grants – Roche, Sandoz-Novartis, Celltrion, Takeda, NovoNordisk, Celgene. Monika Długosz Danecka: Research Grants – Roche, Sandoz-Novartis, Celltrion, Takeda, NovoNordisk, Celgene. Gilles Salles: Advisory board, Consultancy or participation in Educational events – Abbvie, Amgen, Autolus, BMS/Celgene, Debiopharm, Genmab, Kite/Gilead, Epizyme, Janssen, Karyopharm, MorphoSys, Novartis, Roche, Takeda. Hervé Ghesquières: Consultancy – Gilead Sciences, Celgene, Roche; honoraria – Gilead Sciences, Janssen, Celgene; travel, accommodations, or expenses – Roche, Gilead Sciences, Celgene, Takeda. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed."

"Funding This article is funded by MorphoSys AG."